RNLXライブシグナル | Getagraph.comで利益を最大化

売る 107754 min ago

@ $1.190

発行日: 15 2月 2024 @ 05:54

リターン: -43.19%

前回のシグナル: 2月 15 - 03:31

前回のシグナル: 買う

リターン: 3.48 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Stats
本日の出来高	448 805
平均出来高	1.92M
時価総額	43.11M
EPS	$-0.110 ( 2023-11-14 )
次の収益日	( $-0.0800 ) 2024-06-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.750
ATR14	$0.00300 (0.44%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Icahn School Of Medicine At Mount Sinai	Buy	9 360 374	Ordinary Shares
2023-11-20	Coste Catherine	Buy	95 000	Employee Stock Option (right to buy)
2023-11-20	Levangie Daniel J	Buy	95 000	Employee Stock Option (right to buy)
2023-11-20	Parikh Chirag R.	Buy	95 000	Employee Stock Option (right to buy)
2023-11-20	Mills Christopher	Buy	95 000	Employee Stock Option (right to buy)

INSIDER POWER
84.25
Last 27 transactions
Buy: 12 713 670 \| Sell: 1 641 743

ボリューム相関

長: -0.02 (neutral)

短: 0.35 (neutral)

Signal:(58.089) Neutral

Renalytix AI plc 相関

10 最も正の相関
PUCK	0.925
NVCN	0.921
TWLV	0.92
TWCB	0.92
KSICU	0.919
GXII	0.918
OVID	0.917
UBFO	0.916
TBLA	0.915
KVSA	0.914

10 最も負の相関
AMGN	-0.943
NAKD	-0.921
CYTO	-0.921
AHPI	-0.913
HCAQ	-0.909
PROC	-0.905
LAWS	-0.905
THMA	-0.896
PCSA	-0.894
LSAQ	-0.892

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Renalytix AI plc 相関 - 通貨/商品

0.31
( neutral )

-0.25
( neutral )

0.00
( neutral )

0.14
( neutral )

Renalytix AI plc 財務諸表

Annual	2023
収益:	$3.40M
総利益:	$701 000 (20.60 %)
EPS:	$-1.120

FY	2023
収益:	$3.40M
総利益:	$701 000 (20.60 %)
EPS:	$-1.120

FY	2022
収益:	$2.97M
総利益:	$918 000 (30.91 %)
EPS:	$-1.560

FY	2021
収益:	$1.49M
総利益:	$633 000 (42.45 %)
EPS:	$-0.860

Financial Reports:

No articles found.

Renalytix AI plc

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.